Tumor growth inhibition by intratumoral inoculation of defective herpes simplex virus vectors expressing granulocyte - Macrophage colony-stimulating factor

Molecular Therapy

Volumn 2, Issue 4, 2000, Pages 324-329

  Toda, Masahiro ^a,c   Martuza, Robert L ^a   Rabkin, Samuel D ^a,b  

^a GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^b KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Cancer therapy; GM CSF; Harding Passey; Herpes simplex virus; Melanoma

Indexed keywords

HERPES; MURINAE; SIMPLEXVIRUS;

GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR;

ANIMAL; ARTICLE; BIOSYNTHESIS; C57BL MOUSE; CELL CULTURE; CYTOTOXICITY; DEFECTIVE VIRUS; DOSE RESPONSE; EXPERIMENTAL MELANOMA; GENE EXPRESSION; GENE THERAPY; GENE TRANSFER; GENE VECTOR; GENETICS; HERPES SIMPLEX VIRUS; METABOLISM; MOUSE; PATHOLOGY; SUBCUTANEOUS DRUG ADMINISTRATION; SURVIVAL RATE; TRANSGENE;

ANIMALS; CYTOTOXICITY, IMMUNOLOGIC; DEFECTIVE VIRUSES; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE EXPRESSION; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; INJECTIONS, SUBCUTANEOUS; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; SIMPLEXVIRUS; SURVIVAL RATE; TRANSGENES; TUMOR CELLS, CULTURED;

EID: 0034294865     PISSN: 15250016     EISSN: None     Source Type: Journal    
DOI: 10.1006/mthe.2000.0130     Document Type: Article

References (41)

1. Parmiani, G., Colombo, M. P., Melani, C., and Arienti, F. (1997). Cytokine gene transduction in the immunotherapy of cancer. Adv. Pharmacol. 40: 259-307.
2. Jaffee, E. M. (1999). Immunotherapy of cancer. Ann. N.Y. Acad. Sci. 886: 67-72.
3. Dranoff, G., et al. (1993). Vaccination with irradiated tumor cells engineered to secrete murine granulocyte - macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc. Natl. Acad. Sci. USA 90: 3539-3543.
4. Zhang, J., and Russell, S. J. (1996). Vectors for cancer gene therapy. Cancer Metastasis Rev. 15: 385-401.
5. Gansbacher, B., et al. (1992). Retroviral gene transfer induced constitutive expression of interleukin-2 or interferon-gamma in irradiated human melanoma cells. Blood 80: 2817-2825.
6. Tahara, H., et al. (1995). Effective eradication of established murine tumors with IL-12 gene therapy using a polycistronic retroviral vector. J. Immunol, 154: 6466-6474.
7. Bramson, J. L., Hitt, M., Addison, C. L., Muller, W. J., Gauldie, J., and Graham, F. L. (1996). Direct intratumoral injection of an adenovirus expressing interleukin-12 induces regression and long-lasting immunity that is associated with highly localized expression of interleukin-12. Hum. Gene Ther. 7: 1995-2002.
8. Meko, J. B., Yim, J. H., Tsung, K., and Norton, J. A. (1995). High cytokine production and effective antitumor activity of a recombinant vaccinia virus encoding murine interleukin 12. Cancer Res. 55: 4765-4770.
9. Qin, H. X., and Chatterjee, S. K. (1996). Cancer gene therapy using tumor cells infected with recombinant vaccinia virus expressing GM-CSF. Hum. Gene Ther. 7: 1853-1860.
10. Spaete, R., and Frankel, N. (1982). The herpes simplex virus amplicon: A new eucaryotic defective-virus cloning-amplifying vector. Cell 30: 305-310.
11. Brooks, A. I., Halterman, M. W., and Federoff, H. J. (1997). Use of the herpes amplicon system as a vehicle for somatic gene transfer. Adv. Drug Deliv. Rev. 27: 29-39.
12. Geller, A. I., and Breakefield, X. O. (1988). A defective HSV-1 vector expresses Escherichia coli beta-galactosidase in cultured peripheral neurons. Science 241: 1667-1669.
13. Jones, T., Stern, A., and Lin, R. (1994). Potential role of granulocyte - macrophage colony-stimulating factor as a vaccine adjuvant Eur. J. Clin. Microbiol. Infect. Dis. 13: 47S-53S.
14. Pardoll, D. M. (1995). Paracrine cytokine adjuvants in cancer immunotherapy. Annu. Rev. Immunol. 13: 399-415.
15. Steinman, R. M. (1991). The dendritic cell system and its role in immunogenicity. Annu. Rev. Immunol. 9: 271-296.
16. Simons, J. W., et al. (1997). Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex vivo granulocyte - macrophage colony-stimulating factor gene transfer. Cancer Res. 57: 1537-1546.
17. Simons, J. W., et al. (1999). Induction of immunity to prostate cancer antigens: Results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte - macrophage colony-stimulating factor using ex vivo gene transfer. Cancer Res. 59: 5160-5168.
18. Ellem, K. A., et al. (1997). A case report: Immune responses and clinical course of the first human use of granulocyte/macrophage-colony-stimulating-factor-transduced autologous melanoma cells for immunotherapy. Cancer Immunol. Immunother. 44: 10-20.
19. Yasamura, Y., Tashjian, A. H., Jr., and Sato, G. H. (1966). Establishment of four functional, clonal strains of animal cells in culture. Science 154: 1186-1189.
20. Harding, H. E., and Passey, R. D. (1930). A transplantable melanoma of the mouse. J. Pathol. Bacteriol. 33: 417.
21. Bleehen, S. S. (1974). Ultrastructural studies on tumors and cell cultures of the Harding-Passey mouse melanoma. Br. J. Dermatol. 90: 637-648.
22. Castillo, R., Diaz, J. W., Veloso, A., and Gavilondo, J. (1982). Leukomoid reaction induced by different transplantable tumors in three inbred mouse strains. Neoplasma 29: 73-79.
23. Fidler, I. J. (1973). Selection of successive tumor cell lines for metastasis. Nature 242: 148-149.
24. Brattain, M. G., Strobel-Stevens, J., Fine, D., Webb, M., and Sarrif, A. M. (1980). Establishment of mouse colonic carcinoma cell lines with different metastatic properties. Cancer Res. 40: 2142-2146.
25. Seligman, A. M., and Shear, M. J. (1939). Studies in carcinogenesis. VIII. Experimental production of brain tumors in mice with methylcholanthrene. Am. J. Cancer 37: 364-395.
26. Ausman, J. I., Shapiro, W. R., and Rail, D. P. (1970). Studies on the chemotherapy of experimental brain tumors: Development of an experimental model. Cancer Res. 30: 2394-2400.
27. Miyatake, S., Martuza, R. L., and Rabkin, S. D. (1997). Defective herpes simplex virus vectors expressing thymidine kinase for the treatment of malignant glioma. Cancer Gene Ther. 4: 222-228.
28. New, K. C., Gale, K., Martuza, R. L., and Rabkin, S. D. (1998). Novel synthesis and release of GABA in cerebellar granule cell cultures after infection with defective herpes simplex virus vectors expressing glutamic acid decarboxylase. Mol. Brain Res. 61: 121-135.
29. Kaplitt, M. G., Pfeus, J. G., Kleopoulou, S. P., Hanlon, B. A., Rabkin, S. D., and Pfaff, D. W. (1991). Expression of a functional foreign gene in adult mammalian brain following in vivo transfer via a herpes simplex virus type 1 defective viral vector. Mol. Cell. Neurosci. 2: 320-330.
30. Toda, M., Martuza, R. L., Kojima, H., and Rabkin, S. D. (1998). In situ cancer vaccination: An IL-12 defective vector/replication-competent herpes simplex virus combination induces local and systemic antitumor activity. J. Immunol. 160: 4457-4464.
31. Miyatake, S., Otsuka, T., Yokota, T., Lee, F., and Arai, K. (1985). Structure of the chromosomal gene for granulocyte - macrophage colony stimulating factor: Comparison of the mouse and human genes. EMBO J. 4: 2561-2568.
32. Davison, M. J., Preston, V. G., and McGeoch, D. J. (1984). Determination of the sequence alteration in the DNA of the herpes simplex virus type 1 temperature-sensitive mutant tsK. J. Gen. Virol. 65: 859-863.
33. Randazzo, B. P., et al. (1995). Treatment of experimental intracranial murine melanoma with a neuroattenuated herpes simplex virus 1 mutant. Virology 211: 94-101.
34. Watson, K., Stevens, J. G., Cook, M. L., and Subak-Sharpe, J. H. (1980). Latency competence of thirteen HSV-1 temperature-sensitive mutants. J. Gen. Virol. 49: 149-159.
35. Gerdes, J. C., Marsden, H. S., Cook, M. L., and Stevens, J. G. (1979). Acute infection of differentiated neuroblastoma cells by latency-positive and latency-negative herpes simplex virus ts mutants. Virology 94: 430-441.
36. Rosenberg, S. A. (1990). Adoptive immunotherapy for cancer. Sci. Am. 262: 34-39.
37. Brunda, M. J., et al. (1993). Antitumor and antimetastatic activity of interleukin 12 against murine tumors. J. Exp. Med. 178: 1223-1230.
38. Karpoff, H. M., D'Angelica, M., Blair, S., Brownlee, M. D., Federoff, H., and Fong, Y. (1997). Prevention of hepatic tumor metastases in rats with herpes viral vaccines and gamma-interferon. J. Clin. Invest. 99: 799-804.
39. Tung, C., et al. (1996). Rapid production of interleukin-2-secreting tumor cells by herpes simplex virus-mediated gene transfer: Implications for autologous vaccine production. Hum. Gene Ther. 7: 2217-2221.
40. Toda, M., Rabkin, S. D., Kojima, H., and Martuza, R. L. (1999). Herpes simplex virus as an in situ cancer vaccine for the induction of specific anti-tumor immunity. Hum. Gene Ther. 10: 385-393.
41. Romani, N., et al. (1989). Presentation of exogenous protein antigens by dendritic cells to T cell clones. J. Exp. Med. 169: 1169-1178.